Clinical Research Directory

Inclusion Criteria: 1. Male subject with symptomatic BPH NOTE: Symptomatic BPH is defined as an International Prostate Symptom Score (IPSS) ≥ 13 and peak urinary flow rate (Qmax) of ≤15 mL/sec 2. Prostate dimensions suitable for treatment with the Optilume BPH Catheter System in accordance with the approved Instructions for Use NOTE: Prostate volume between 20 to 80 gm and prostatic urethral length between 32 mm and 55 mm as determined by TRUS 3. Able to complete the study protocol in the opinion of the investigator Exclusion Criteria: 1. Unable or unwilling to sign the Informed Consent Form (ICF) and/or comply with follow-up requirements 2. Unwilling to abstain from sexual intercourse or use a condom for 30 days post-procedure and a highly effective contraceptive for at least 6 months post-procedure 3. Presence of an artificial urinary sphincter or stent(s) in the urethra or prostate 4. Any prior minimally invasive intervention (e.g. TUNA, Balloon, Microwave, Rezūm, UroLift) or surgical intervention of the prostate 5. Confirmed or suspected malignancy of prostate or bladder 6. Active urinary tract infection (UTI) confirmed by culture 7. History of overt urinary incontinence requiring use of pads NOTE: Pad usage for post-micturition dribble is acceptable 8. Presence of confounding diagnoses impacting lower urinary tract symptoms or bladder function (e.g. urethral strictures, bladder neck contracture, neurogenic bladder, detrusor instability, bladder stones, etc.) 9. History of chronic urinary retention (e.g. PVR ≥300mL on two separate occasions, or catheter dependent drainage) 10. Anatomy (e.g. presence of false passage or size of meatus) is not suitable for treatment with the Optilume BPH Catheter System 11. Significant obstruction from median lobe in the opinion of the investigator 12. Disease or other health condition that is not suitable for this study